Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad M. Robins sold 5,560 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $22.89, for a total value of $127,268.40. Following the sale, the chief executive officer now owns 1,889,300 shares of the company’s stock, valued at approximately $43,246,077. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ:ADPT opened at $25.29 on Thursday. The stock has a fifty day moving average price of $27.38 and a two-hundred day moving average price of $29.73. Adaptive Biotechnologies Corporation has a 1 year low of $15.19 and a 1 year high of $55.12.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). The business had revenue of $24.21 million during the quarter, compared to analysts’ expectations of $21.64 million. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.96 EPS for the current year.

Separately, Zacks Investment Research cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.83.

A number of large investors have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co NY purchased a new position in Adaptive Biotechnologies in the third quarter worth $30,000. CIBC Private Wealth Group LLC raised its position in Adaptive Biotechnologies by 11.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 11,500 shares of the company’s stock worth $344,000 after acquiring an additional 1,150 shares in the last quarter. TD Asset Management Inc. raised its position in Adaptive Biotechnologies by 6.8% in the fourth quarter. TD Asset Management Inc. now owns 26,832 shares of the company’s stock worth $803,000 after acquiring an additional 1,700 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Adaptive Biotechnologies by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 91,896 shares of the company’s stock worth $2,750,000 after acquiring an additional 1,795 shares in the last quarter. Finally, First Mercantile Trust Co. purchased a new position in Adaptive Biotechnologies in the fourth quarter worth $72,000. Hedge funds and other institutional investors own 68.25% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.

Read More: Support Level

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.